AEGiS-GMHC: DRUG WATCH: First U.S. HIV Antisense Trial Starts

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

DRUG WATCH: First U.S. HIV Antisense Trial Starts

Gay Men's Health Crisis: Treatment Issues, Volume 8 no. 4 - June 1994
David Gold and Dave Gilden

Hybridon, a Worcester, Massachusetts based biotechnology company, received FDA approval to test its antisense product, GEM-91, which disrupts a sequence on the HIV gag gene essential for constructing the core of new virus particles. Trials are to begin by the end of April at the University of Alabama and will include six HIV-positive patients. Michael Saag is the principal investigator. GEM-91 is administered intravenously. The drug has been studied in 23 patients in France without side effects. However, in primates, serious cardiovascular side effects were seen. In test tubes, GEM-91 inhibits HIV replication.

Copyright (c) 1994 - GMHC Treatment Issues. Noncommercial reproduction encouraged. Distributed by AEGIS, your online gateway to a world of people, knowledge, and resources. Direct Dial: v.34+: 714.248.2836; v.120/ISDN: 714.248.0433 Internet: telnet:aegis.com www: www.aegis.com
9406
GM080408

Copyright © 1994 - Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, Inc. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 fredg@gmhc.org http://www.gmhc.org

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .